# Julie Grant

> Julie Grant is a General Partner at Canaan, a $5B technology and healthcare venture capital firm, where she leads biopharma investments and company formation on the West Coast. She co-founded and served as founding CEO of Day One Biopharmaceuticals, a purpose-built pediatric oncology company that grew to a $1.5B+ valuation and was later acquired by Servier. A Yale-educated molecular biophysicist who went on to Stanford MBA and Cambridge MPhil, Grant brings rare operational depth to venture - having sat in the CEO chair before returning to investing. In 2023, President Biden appointed her to the National Cancer Advisory Board. She is the fourth woman to become a General Partner at Canaan.

- **Role:** General Partner at Canaan
- **Organizations:** Canaan, Day One Biopharmaceuticals, Synthekine, Nocion Therapeutics, National Cancer Advisory Board, Protagonist Therapeutics
- **From:** Chicago, United States
- **Nationality:** American
- **Education:** B.S. in Molecular Biophysics and Biochemistry, Yale University, M.Phil. in BioScience Enterprise, Cambridge University, M.B.A., Stanford Graduate School of Business
- **Known for:** Co-founded and served as founding CEO of Day One Biopharmaceuticals, a pediatric oncology company that grew to $1.5B+ valuation, Fourth woman to become General Partner at Canaan, Appointed to the National Cancer Advisory Board by President Biden in 2023

## Career timeline

- **pre-2013** — Early career at Goldman Sachs in finance
- **pre-2013** — Joined Genentech in oncology commercial, business development, and cross-functional management roles
- **2013** — Joined Canaan as investor, eventually rising to General Partner
- **2018** — Co-founded Day One Biopharmaceuticals with Dr. Sam Blackman; served as founding CEO
- **2018** — Day One raises $60M Series A from Canaan, Atlas Venture, and Access Biotechnology
- **2017** — Named to San Francisco Business Times 40 Under 40
- **2021** — Day One Biopharmaceuticals reaches $1.5B+ valuation
- **2023** — Appointed by President Biden to the National Cancer Advisory Board
- **2024** — Day One Biopharmaceuticals acquired by Servier

## Achievements

- Co-founded and served as founding CEO of Day One Biopharmaceuticals, a pediatric oncology company that grew to $1.5B+ valuation
- Fourth woman to become General Partner at Canaan
- Appointed to the National Cancer Advisory Board by President Biden in 2023
- San Francisco Business Times 40 Under 40, Class of 2017
- College sailing national champion
- Biked 4,000 miles across the United States to raise money for Habitat for Humanity
- Led investments and company formation in a portfolio including multiple IPOs and acquisitions: Day One (Servier), Cellular Research (Becton Dickinson), Protagonist (IPO), Dermira (IPO)
- Incubated and financed Nocion Therapeutics and Synthekine at Canaan

## Latest updates

- **2024-12** — Featured on BioVenture VoiCes podcast discussing Canaan's biopharma investment approach
- **2024-04** — Day One Biopharmaceuticals acquired by Servier; Grant continues as General Partner at Canaan
- **2023-02** — Appointed by President Biden to the National Cancer Advisory Board

## Links

- Website: https://canaan.com/team/julie-grant
- LinkedIn: http://www.linkedin.com/in/julie-grant-a8961b1
- Twitter/X: https://twitter.com/JuliePapanek
- Facebook: https://facebook.com/CanaanPartners

---

Profile page: https://yespress.io/julie-grant
Published by YesPress — https://yespress.io
Last updated: 2026-05-18